Despite compelling single agent anti-tumor activity in preclinical models of diverse tumor types, the reported clinical response to DR5 agonists in cancer patients has been restricted to a few partial responses in patients [3,4], highlighting a need to better predict DR5 agonist responsive patients. The gene discussed is TNFRSF10B; the disease is cancer.